The COVID-19 pandemic has thrown multiple operational and financial challenges for organisations and businesses across the world.
GlobalData has conducted a survey to assess the primary concerns for pharmaceutical businesses related to the COVID-19 outbreak in Q1 and Q3 2020.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Primary concerns for pharmaceutical businesses related to the COVID-19 outbreak
Analysis of the survey results shows that employee safety remained the primary concern between Q1 and Q3 and the concern has only increased.
A majority 21% of the respondents opined that employee safety was their primary business concern in Q1, which increased to 23% in Q3.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataImpact on supply chains was the next biggest concern as opined by 20% in Q1 and 19% in Q3.
While 16% of the respondents opined that clinical trial disruption was the primary concern in Q1, the percentage declined to 15% in Q3. Concerns over CRO disruptions increased in Q3 to 12%, from 10% in Q1.
Money raising was considered as the primary concern by 10% of the respondents in Q1, but declined to 9% in Q3. Respondents considering business development as a primary concern increased from 8% in Q1 to 9% in Q3.
Another 7% voted that medical meeting closures were the primary concern in Q1, which declined to 4% in Q3, while 6% voted for sales representatives’ access to physicians as the primary concern in Q1, which declined to 5% in Q3 and 2% listed other reasons as their primary concerns in Q1, which increased to 3% in Q3.
The analysis is based on responses received from the Pharmaceutical Trade and Supply Chain Survey fielded between 07 July and 30 July 2020.
